Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2011

01.01.2011 | Original Article

Mechanism of Acid Hypersecretion Post Curative Gastrinoma Resection

verfasst von: Jeremiah V. Ojeaburu, Tetsuhide Ito, Pellegrino Crafa, Cesare Bordi, Robert T. Jensen

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Some patients with Zollinger-Ellison syndrome post curative gastrinoma resection continue to show gastric acid hypersecretion; however, the mechanism is unknown.

Aim

The aim of this study was to prospectively study acid secretion following curative gastrinoma resection and analyze factors contributing in patients with Zollinger-Ellison syndrome.

Methods

Fifty patients cured post gastrinoma resection were studied with serial assessments of acid secretory status, cure status and ECL-cell status/activity (with serial biopsies, CgA, urinary N-MIAA). Correlative analysis was performed to determine predictive factors.

Results

Hypersecretion occurred in 31 patients (62%) and 14 had extreme-hypersecretion. There was an initial decline (3–6 months) in BAO/MAO, which then remained stable for eight years. Preoperative BAO correlated with the postoperative secretion, but not other clinical, tumoral, laboratory variables, the degree of postoperative acid suppression or type of antisecretory drug needed. Hypersecretors had greater postoperative ECL changes (P = 0.005), serum CGA (P = 0.009) and 24-h urinary N-MIAA (P = 0.0038).

Conclusions

Post curative resection, gastric hypersecretion persists long term (mean 8 years) in 62% of patients and in 28% it is extreme, despite normogastrinemia. No preoperative variable except BAO correlates with postresection hypersecretion. The persistent increased ECL-cell extent post curative resection suggests prolonged hypergastrinemia can lead to changes in ECL-cells that are either irreversible in humans or sustained by unknown mechanisms not involving fasting hypergastrinemia and which can result in hypersecretion, in a proportion of which it can be extreme. Whether similar findings may occur in patients with idiopathic GERD treated for prolonged periods (>10 years) with PPIs, at present, is unknown.
Literatur
1.
Zurück zum Zitat Jensen RT, Niederle B, Mitry E, Ramage JK, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84:173–182.CrossRefPubMed Jensen RT, Niederle B, Mitry E, Ramage JK, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84:173–182.CrossRefPubMed
2.
Zurück zum Zitat Roy P, Venzon DJ, Feigenbaum KM, Koviack PD, et al. Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis—A prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore). 2001;80:189–222.CrossRef Roy P, Venzon DJ, Feigenbaum KM, Koviack PD, et al. Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis—A prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore). 2001;80:189–222.CrossRef
3.
Zurück zum Zitat Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757–773.CrossRefPubMed Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757–773.CrossRefPubMed
4.
Zurück zum Zitat Maton PN, Dayal Y. Clinical implications of hypergastrinemia. In: Zakim D, Dannenberg AJ, eds. Peptic Ulcer Disease and Other Acid-Related Disorders. Armonk, NY: Academic Research Associates; 1991:213–246. Maton PN, Dayal Y. Clinical implications of hypergastrinemia. In: Zakim D, Dannenberg AJ, eds. Peptic Ulcer Disease and Other Acid-Related Disorders. Armonk, NY: Academic Research Associates; 1991:213–246.
5.
Zurück zum Zitat Peghini PL, Annibale B, Azzoni C, Milione M, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123:68–85.CrossRefPubMed Peghini PL, Annibale B, Azzoni C, Milione M, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123:68–85.CrossRefPubMed
6.
Zurück zum Zitat Maton PN, Lack EE, Collen MJ, Cornelius MJ, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology. 1990;99:943–950.PubMed Maton PN, Lack EE, Collen MJ, Cornelius MJ, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology. 1990;99:943–950.PubMed
7.
Zurück zum Zitat Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion. 1988;39:61–79.PubMed Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion. 1988;39:61–79.PubMed
8.
Zurück zum Zitat Jensen RT. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol Toxicol. 2002;91:333–350.CrossRefPubMed Jensen RT. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol Toxicol. 2002;91:333–350.CrossRefPubMed
9.
Zurück zum Zitat Jensen RT. Gastrinoma as a model for prolonged hypergastrinemia in man. In: Walsh JH, ed. Gastrin. New York, NY: Raven Press Publishing Co; 1993:373–393. Jensen RT. Gastrinoma as a model for prolonged hypergastrinemia in man. In: Walsh JH, ed. Gastrin. New York, NY: Raven Press Publishing Co; 1993:373–393.
10.
Zurück zum Zitat Richter JE. Gastroesophageal reflux disease. In: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW, eds. Textbook of Gastroenterology. Oxford, UK: Blackwell; 2009:772–801. Richter JE. Gastroesophageal reflux disease. In: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW, eds. Textbook of Gastroenterology. Oxford, UK: Blackwell; 2009:772–801.
11.
Zurück zum Zitat Jensen RT. Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4–19.CrossRefPubMed Jensen RT. Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4–19.CrossRefPubMed
12.
Zurück zum Zitat Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, De Bruijne JW, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99:621–628.PubMed Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, De Bruijne JW, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99:621–628.PubMed
13.
Zurück zum Zitat Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85:295–330.CrossRef Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85:295–330.CrossRef
14.
Zurück zum Zitat Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994;121:161–167.PubMed Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994;121:161–167.PubMed
15.
Zurück zum Zitat Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology. 2000;118:661–669.CrossRefPubMed Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology. 2000;118:661–669.CrossRefPubMed
16.
Zurück zum Zitat Solcia E, Bordi C, Creutzfeldt W, Dayal Y, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41:185–200.CrossRefPubMed Solcia E, Bordi C, Creutzfeldt W, Dayal Y, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41:185–200.CrossRefPubMed
17.
Zurück zum Zitat Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol. 2005;19:659–673.CrossRefPubMed Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol. 2005;19:659–673.CrossRefPubMed
18.
Zurück zum Zitat Wangberg B, Nilsson O, Theodorsson E, Modlin IM, et al. Are enterochromaffinlike cell tumours reversible? An experimental study on gastric carcinoids induced in Mastomys by histamine2-receptor blockade. Regul Pept. 1995;56:19–33.CrossRefPubMed Wangberg B, Nilsson O, Theodorsson E, Modlin IM, et al. Are enterochromaffinlike cell tumours reversible? An experimental study on gastric carcinoids induced in Mastomys by histamine2-receptor blockade. Regul Pept. 1995;56:19–33.CrossRefPubMed
19.
Zurück zum Zitat Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol. 2001;15:487–495.CrossRefPubMed Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol. 2001;15:487–495.CrossRefPubMed
20.
Zurück zum Zitat Hunfeld NG, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25:39–46.CrossRefPubMed Hunfeld NG, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25:39–46.CrossRefPubMed
21.
Zurück zum Zitat Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol 2009;45:389–394. Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol 2009;45:389–394.
22.
Zurück zum Zitat Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21:149–154.CrossRefPubMed Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21:149–154.CrossRefPubMed
23.
Zurück zum Zitat Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–87.CrossRefPubMed Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–87.CrossRefPubMed
24.
Zurück zum Zitat Berna MJ, Annibale B, Marignani M, Luong TV, et al. A prospective study of gastric carcinoids and enterochromaffin-like cells changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metabol. 2008;93:1582–1591.CrossRef Berna MJ, Annibale B, Marignani M, Luong TV, et al. A prospective study of gastric carcinoids and enterochromaffin-like cells changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metabol. 2008;93:1582–1591.CrossRef
25.
Zurück zum Zitat Norton JA, Alexander HR, Fraker DL, Venzon DJ, Jensen RT. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg. 2004;239:617–626.CrossRefPubMed Norton JA, Alexander HR, Fraker DL, Venzon DJ, Jensen RT. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg. 2004;239:617–626.CrossRefPubMed
26.
Zurück zum Zitat Pisegna JR, Norton JA, Slimak GG, Metz DC, et al. Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology. 1992;102:767–778.PubMed Pisegna JR, Norton JA, Slimak GG, Metz DC, et al. Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology. 1992;102:767–778.PubMed
27.
Zurück zum Zitat Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199–206.PubMed Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199–206.PubMed
28.
Zurück zum Zitat Berna MJ, Hoffmann KM, Long SH, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006;85:331–364.CrossRef Berna MJ, Hoffmann KM, Long SH, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006;85:331–364.CrossRef
29.
Zurück zum Zitat Bordi C, Azzoni C, Ferraro G, Corleto VD, et al. Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol. 2000;114:419–425.PubMed Bordi C, Azzoni C, Ferraro G, Corleto VD, et al. Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol. 2000;114:419–425.PubMed
30.
Zurück zum Zitat Goebel SU, Serrano J, Yu F, Gibril F, et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer. 1999;85:1470–1483.CrossRefPubMed Goebel SU, Serrano J, Yu F, Gibril F, et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer. 1999;85:1470–1483.CrossRefPubMed
31.
Zurück zum Zitat Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol. 1997;32:198–202.CrossRefPubMed Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol. 1997;32:198–202.CrossRefPubMed
32.
Zurück zum Zitat Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther. 1999;13:145–153.CrossRefPubMed Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther. 1999;13:145–153.CrossRefPubMed
33.
Zurück zum Zitat Granerus G. Effects of oral histamine, histidine and diet on urinary excretion of histamine, methylhistamine and 1-methyl-4-imidazoleacetic acid in man. Scand J Clin Lab Invest. 1968;104:49–58. Granerus G. Effects of oral histamine, histidine and diet on urinary excretion of histamine, methylhistamine and 1-methyl-4-imidazoleacetic acid in man. Scand J Clin Lab Invest. 1968;104:49–58.
34.
Zurück zum Zitat Bashir S, Gibril F, Ojeaburu J, Asgharian B, et al. Prospective study of the ability of histamine, serotonin or chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther. 2002;16:1367–1382.CrossRefPubMed Bashir S, Gibril F, Ojeaburu J, Asgharian B, et al. Prospective study of the ability of histamine, serotonin or chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther. 2002;16:1367–1382.CrossRefPubMed
35.
Zurück zum Zitat Norton JA, Fraker DL, Alexander HR, Venzon DJ, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–644.CrossRefPubMed Norton JA, Fraker DL, Alexander HR, Venzon DJ, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–644.CrossRefPubMed
36.
Zurück zum Zitat Krudy AG, Doppman JL, Jensen RT, Norton JA, et al. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol. 1984;143:585–589. Krudy AG, Doppman JL, Jensen RT, Norton JA, et al. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol. 1984;143:585–589.
37.
Zurück zum Zitat Gibril F, Reynolds JC, Chen CC, Yu F, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40:539–553.PubMed Gibril F, Reynolds JC, Chen CC, Yu F, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40:539–553.PubMed
38.
Zurück zum Zitat Gibril F, Doppman JL, Reynolds JC, Chen CC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol. 1998;16:1040–1053.PubMed Gibril F, Doppman JL, Reynolds JC, Chen CC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol. 1998;16:1040–1053.PubMed
39.
Zurück zum Zitat Doppman JL, Miller DL, Chang R, Maton PN, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990;174:25–29.PubMed Doppman JL, Miller DL, Chang R, Maton PN, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990;174:25–29.PubMed
40.
Zurück zum Zitat Alexander HR, Fraker DL, Norton JA, Barlett DL, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998;228:228–238.CrossRefPubMed Alexander HR, Fraker DL, Norton JA, Barlett DL, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998;228:228–238.CrossRefPubMed
41.
Zurück zum Zitat Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med. 1998;243:477–488.CrossRefPubMed Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med. 1998;243:477–488.CrossRefPubMed
42.
Zurück zum Zitat Norton JA, Alexander HR, Fraker DL, Venzon DJ, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234:495–506.CrossRefPubMed Norton JA, Alexander HR, Fraker DL, Venzon DJ, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234:495–506.CrossRefPubMed
43.
Zurück zum Zitat Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine. 2004;83:43–83.CrossRefPubMed Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine. 2004;83:43–83.CrossRefPubMed
44.
Zurück zum Zitat Frucht H, Norton JA, London JF, Vinayek R, et al. Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology. 1990;99:1622–1627.PubMed Frucht H, Norton JA, London JF, Vinayek R, et al. Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology. 1990;99:1622–1627.PubMed
45.
Zurück zum Zitat Benya RV, Metz DC, Venzon DJ, Fishbeyn VA, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med. 1994;97:436–444.CrossRefPubMed Benya RV, Metz DC, Venzon DJ, Fishbeyn VA, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med. 1994;97:436–444.CrossRefPubMed
46.
Zurück zum Zitat Aprile MR, Azzoni C, Gibril F, Jensen RT, Bordi C. Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome. Hum Pathol. 2000;31:140–148.CrossRefPubMed Aprile MR, Azzoni C, Gibril F, Jensen RT, Bordi C. Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome. Hum Pathol. 2000;31:140–148.CrossRefPubMed
47.
Zurück zum Zitat Roy P, Venzon DJ, Shojamanesh H, Abou-Saif A, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine. 2000;79:379–411.CrossRefPubMed Roy P, Venzon DJ, Shojamanesh H, Abou-Saif A, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine. 2000;79:379–411.CrossRefPubMed
48.
Zurück zum Zitat Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103:1498–1508.PubMed Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103:1498–1508.PubMed
49.
Zurück zum Zitat Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion: comparison with Zollinger-Ellison syndrome. Dig Dis Sci. 1994;39:1434–1440.CrossRefPubMed Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion: comparison with Zollinger-Ellison syndrome. Dig Dis Sci. 1994;39:1434–1440.CrossRefPubMed
50.
Zurück zum Zitat Termanini B, Gibril F, Sutliff VE III, Yu F, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104:422–430.CrossRefPubMed Termanini B, Gibril F, Sutliff VE III, Yu F, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104:422–430.CrossRefPubMed
51.
Zurück zum Zitat Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999;116:239–247.CrossRefPubMed Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999;116:239–247.CrossRefPubMed
52.
Zurück zum Zitat Metz DC, Weber HC, Orbuch M, Strader DB, et al. Helicobacter pylori infection: a reversible cause of hypergastrinemia and hyperchlorhydria which can mimic Zollinger-Ellison syndrome. Dig Dis Sci. 1995;40:153–159.CrossRefPubMed Metz DC, Weber HC, Orbuch M, Strader DB, et al. Helicobacter pylori infection: a reversible cause of hypergastrinemia and hyperchlorhydria which can mimic Zollinger-Ellison syndrome. Dig Dis Sci. 1995;40:153–159.CrossRefPubMed
53.
Zurück zum Zitat Weber HC, Venzon DJ, Jensen RT, Metz DC. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori and proton pump inhibitor therapy. Gastroenterology. 1997;112:84–91.CrossRefPubMed Weber HC, Venzon DJ, Jensen RT, Metz DC. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori and proton pump inhibitor therapy. Gastroenterology. 1997;112:84–91.CrossRefPubMed
54.
Zurück zum Zitat Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993;104:1356–1370.PubMed Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993;104:1356–1370.PubMed
55.
Zurück zum Zitat Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol. 1985;20(Suppl 108):53–69. Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol. 1985;20(Suppl 108):53–69.
56.
Zurück zum Zitat Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf. 2002;1:29–38.CrossRefPubMed Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf. 2002;1:29–38.CrossRefPubMed
57.
Zurück zum Zitat Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion—tolerance and rebound. Aliment Pharmacol Ther. 1997;11:1013–1018.CrossRefPubMed Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion—tolerance and rebound. Aliment Pharmacol Ther. 1997;11:1013–1018.CrossRefPubMed
58.
Zurück zum Zitat McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology. 2009;137:20–22.CrossRefPubMed McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology. 2009;137:20–22.CrossRefPubMed
59.
Zurück zum Zitat Larsson H, Carlsson E, Ryberg B, Fryklund J, Wallmark B. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am J Physiol. 1988;254:G33–G39.PubMed Larsson H, Carlsson E, Ryberg B, Fryklund J, Wallmark B. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am J Physiol. 1988;254:G33–G39.PubMed
60.
Zurück zum Zitat LePard KJ, Mohammed JR, Stephens RL Jr. Gastric ECL-cell hyperplasia produces enhanced basal and stimulated gastric acid output but not gastric erosion formation in the rat. Gen Pharmacol. 1997;28:415–420.PubMed LePard KJ, Mohammed JR, Stephens RL Jr. Gastric ECL-cell hyperplasia produces enhanced basal and stimulated gastric acid output but not gastric erosion formation in the rat. Gen Pharmacol. 1997;28:415–420.PubMed
61.
Zurück zum Zitat Larsson H, Carlsson E, Mattsson H, Lundell L, et al. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology. 1986;90:391–399.PubMed Larsson H, Carlsson E, Mattsson H, Lundell L, et al. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology. 1986;90:391–399.PubMed
62.
Zurück zum Zitat Nishida A, Kobayashi-Uchida A, Akuzawa S, Takinami Y, et al. Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. Am J Physiol. 1995;269:G699–G705.PubMed Nishida A, Kobayashi-Uchida A, Akuzawa S, Takinami Y, et al. Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. Am J Physiol. 1995;269:G699–G705.PubMed
63.
Zurück zum Zitat Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmacology and toxicology of omeprazole—with special reference to the effects on the gastric mucosa. Scand J Gastroenterol (Suppl). 1986;118:31–38.CrossRef Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmacology and toxicology of omeprazole—with special reference to the effects on the gastric mucosa. Scand J Gastroenterol (Suppl). 1986;118:31–38.CrossRef
64.
Zurück zum Zitat Weinstein WM, Ippoliti AF, Lee SW, Weber LJ, Lieberman DA. Acid hypersecretion, parietal cell hyperplasia, and endoscopic changes after withdrawal of long term high dose omeprazole therapy: a prospective study. Gastroenterology. 1996;110(4):A294. Weinstein WM, Ippoliti AF, Lee SW, Weber LJ, Lieberman DA. Acid hypersecretion, parietal cell hyperplasia, and endoscopic changes after withdrawal of long term high dose omeprazole therapy: a prospective study. Gastroenterology. 1996;110(4):A294.
65.
Zurück zum Zitat Larsson H, Carlsson E, Hakanson R, Mattsson H, et al. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Gastroenterology. 1988;95:1477–1486.PubMed Larsson H, Carlsson E, Hakanson R, Mattsson H, et al. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Gastroenterology. 1988;95:1477–1486.PubMed
66.
Zurück zum Zitat Tielemans Y, Chen D, Sundler F, Hakanson R, Willems G. Reversibility of the cell kinetic changes induced by omeprazole in the rat oxyntic mucosa. An autoradiographic study using tritiated thymidine. Scand J Gastroenterol. 1992;27:155–160.CrossRefPubMed Tielemans Y, Chen D, Sundler F, Hakanson R, Willems G. Reversibility of the cell kinetic changes induced by omeprazole in the rat oxyntic mucosa. An autoradiographic study using tritiated thymidine. Scand J Gastroenterol. 1992;27:155–160.CrossRefPubMed
67.
Zurück zum Zitat Chey WY, Chang TM, Park HJ, Lee KY, et al. Non-gastrin secretagogue in ulcerogenic tumors of the pancreas. Ann Intern Med. 1984;101:7–13.PubMed Chey WY, Chang TM, Park HJ, Lee KY, et al. Non-gastrin secretagogue in ulcerogenic tumors of the pancreas. Ann Intern Med. 1984;101:7–13.PubMed
68.
Zurück zum Zitat Chey WY, Chang TM, Lee KY, Sun G, et al. Ulcerogenic tumor syndrome of the pancreas associated with a nongastric acid secretogogue. Ann Surg. 1989;210:139–149.CrossRefPubMed Chey WY, Chang TM, Lee KY, Sun G, et al. Ulcerogenic tumor syndrome of the pancreas associated with a nongastric acid secretogogue. Ann Surg. 1989;210:139–149.CrossRefPubMed
69.
Zurück zum Zitat Jensen RT. Treatment of pancreatic Zollinger-Ellison syndrome and other gastric hypersecretory states. In: Wolfe MM, ed. Therapy of Digestive Disorders. A Companion to Sleisenger and Fordtran’s Gastrointestinal and Liver Diseases. Philadelphia: W.B. Saunders Co; 2000:169–187. Jensen RT. Treatment of pancreatic Zollinger-Ellison syndrome and other gastric hypersecretory states. In: Wolfe MM, ed. Therapy of Digestive Disorders. A Companion to Sleisenger and Fordtran’s Gastrointestinal and Liver Diseases. Philadelphia: W.B. Saunders Co; 2000:169–187.
70.
Zurück zum Zitat Jensen RT, Berna MJ, Bingham MD, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer. 2008;113(7 suppl):1807–1843.CrossRefPubMed Jensen RT, Berna MJ, Bingham MD, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer. 2008;113(7 suppl):1807–1843.CrossRefPubMed
71.
Zurück zum Zitat Kirkpatrick PM Jr, Hirschowitz BI. Duodenal ulcer with unexplained marked basal gastric acid hypersecretion. Gastroenterology. 1980;79:4–10.PubMed Kirkpatrick PM Jr, Hirschowitz BI. Duodenal ulcer with unexplained marked basal gastric acid hypersecretion. Gastroenterology. 1980;79:4–10.PubMed
72.
Zurück zum Zitat Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The Pancreas: Biology, Pathobiology and Disease. New York: Raven Press Publishing Co; 1993:931–978. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The Pancreas: Biology, Pathobiology and Disease. New York: Raven Press Publishing Co; 1993:931–978.
73.
Zurück zum Zitat Howard JM, Chremos AN, Collen MJ, McArthur KE, et al. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology. 1985;88:1026–1033.PubMed Howard JM, Chremos AN, Collen MJ, McArthur KE, et al. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology. 1985;88:1026–1033.PubMed
Metadaten
Titel
Mechanism of Acid Hypersecretion Post Curative Gastrinoma Resection
verfasst von
Jeremiah V. Ojeaburu
Tetsuhide Ito
Pellegrino Crafa
Cesare Bordi
Robert T. Jensen
Publikationsdatum
01.01.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1234-1

Weitere Artikel der Ausgabe 1/2011

Digestive Diseases and Sciences 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.